We are live on ! Find out more

238 hedge funds and large institutions have $2.74B invested in Insmed in 2022 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 93 increasing their positions, 60 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 20

55% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 60

37% more call options, than puts

Call options by funds: $6.73M | Put options by funds: $4.93M

11% more funds holding

Funds holding: 214238 (+24)

7% more capital invested

Capital invested by funds: $2.55B → $2.74B (+$191M)

2.09% less ownership

Funds ownership: 108.1%106.01% (-2.1%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
238
Holders Change
+24
Holders Change %
+11.21%
% of All Funds
4.08%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
45
Increased
93
Reduced
60
Closed
20
Calls
$6.73M
Puts
$4.93M
Net Calls
+$1.8M
Net Calls Change
+$1.47M

INSM Hedge Fund Activity: Q3 2022 in Review

238 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q3 2022, worth a combined $2.74B — up 7.5% from $2.55B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new INSM positions and 20 closed out — a net gain of 25 holders — while 93 added to existing stakes and 60 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $18.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $160M.

  • 238 institutional investors held Insmed (INSM) as of Q3 2022, up from 214 in Q2 2022.
  • Funds reported $2.74B of Insmed stock for Q3 2022, up 7.5% quarter-over-quarter.
  • 45 funds opened new Insmed positions in Q3 2022 and 20 closed out, a net change of +25 holders.
  • The largest Insmed buyer in Q3 2022 was Polar Capital Holdings, an estimated $18.2M added.
  • The largest Insmed seller in Q3 2022 was T. Rowe Price Associates, an estimated $160M sold.

Based on aggregated 13F filings for Q3 2022.